Application of forsythiaside A in preparing medicine for treating ACLY related diseases or medicine for inhibiting ACLY activity and medicine composition

By developing the natural product Forsythiatin A as a highly active ACLY inhibitor and combining it with a pharmaceutical carrier, the problem of insufficient activity of existing ACLY inhibitors is solved, and effective for hyperlipidemia and atherosclerotic diseases are achieved. Treatment significantly reduces triglyceride and cholesterol levels.

CN119015295APending Publication Date: 2024-11-26DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202310613651.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing ATP citrate lyase (ACLY) inhibitors have problems such as insufficient activity, low safety, small structure types and limited efficacy, making it difficult to effectively treat hyperlipidemia and atherosclerosis.

Method used

The natural product Forsythiatin A was developed as a highly active ACLY inhibitor and combined with appropriate pharmaceutical carriers to form a pharmaceutical composition for the treatment of hyperlipidemia and atherosclerotic diseases.

Benefits of technology

Forsythia esterside A significantly inhibits ACLY, reduces triglycerides and cholesterol levels, has good pharmacological effects and development prospects, and can effectively prevent and treat hyperlipidemia and atherosclerosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015295A_ABST
    Figure CN119015295A_ABST
Patent Text Reader

Abstract

The invention discloses an application of forsythiaside A in preparation of an ATP (adenosine triphosphate) citrate lyase (ACLY) inhibitor. In an enzyme activity test, the forsythiaside A has a very significant inhibition effect on ACLY, and the median inhibitory concentration (IC50) is 0.64 + / -0.09 [mu] M; on a cell model, the forsythiaside A can obviously reduce the triglyceride level; animal experiments show that forsythiaside A can reduce the weight, blood sugar, triglyceride, cholesterol level and the like of mice fed by high-fat, high-cholesterol and high-fructose feed. Therefore, the forsythoside A has a potential treatment value on ACLY related diseases, such as hyperlipidemia and atherosclerosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of drug development, and specifically relates to the use of the natural product forsythiaside A in the preparation of ATP citrate lyase (ACLY) inhibitors and in the treatment of hyperlipidemia and atherosclerotic diseases. Background Art

[0002] ATP citrate lyase (ACLY) catalyzes the cleavage of citrate in the body to produce acetyl-CoA and oxaloacetate. Acetyl-CoA is a precursor molecule for the biosynthesis of fatty acids and cholesterol. Citric acid comes from the tricarboxylic acid cycle. ACLY links carbohydrate metabolism and lipid metabolism, plays a key role in glucose and lipid metabolism, and is an effective target for the treatment of diseases related to lipid metabolism disorders. Currently, ACLY inhibitors have been approved for marketing (Nexletol) for the treatment of hyperlipidemia and related atherosclerotic cardiovascular diseases (Expert Opin Pharmaco, 2019, 20(7):791-803), which has allowed researchers to see the medicinal potential of ACLY inhibitors.

[0003] Currently, there are two main categories of ACLY inhibitors. One category is terminal carboxylic acid inhibitors, represented by hydroxycitric acid (HCA), Medica 16, ETC-1002 and SB-204990 (Eur J Med Chem, 2018, 157: 1276-91). The activity of this type of inhibitor is generally poor, with a half inhibitory concentration (IC 50 ) are all above 1 μM, and the target is not specific, with certain cytotoxicity and poor cell membrane permeability. In in vivo experiments, very high concentrations are required to exert their efficacy; the other type is benzenesulfonamide inhibitors, represented by BMS-303141 and NDI-091143 (Nature, 2019, 568(7753): 566-70). This type of inhibitor has good inhibitory activity against ACLY in non-cellular experiments, but there are few reports on the efficacy of cell experiments and in vivo experiments. In summary, the existing ACLY inhibitors have problems such as poor activity, low safety, few structural types, and limited efficacy. The development of new inhibitors will lay the foundation for drug research targeting ACLY.

[0004] Traditional Chinese medicine is an important source of active compounds. The research team found that forsythiaside A from the plant Forsythia suspensa of the Oleaceae family has good ACLY inhibitory activity, IC 50 =0.64±0.09 μM. There is no report on the medicinal potential of forsythiaside A in hyperlipidemia and atherosclerotic diseases. Summary of the invention

[0005] One of the purposes of the present invention is to provide forsythiaside A as a highly active natural ACLY inhibitor, and the second purpose of the present invention is to provide a new medical use of forsythiaside A.

[0006]

[0007] Specifically, the novel medical use of the present invention is to provide the use of Forsythiaside A in the preparation of drugs for treating hyperlipidemia or atherosclerosis.

[0008] The present invention shows that: Forsythiaside A has a very significant inhibitory effect on ACLY and can reduce the levels of triglycerides and cholesterol. Therefore, Forsythiaside A can be used to prepare drugs for preventing and treating hyperlipidemia or atherosclerosis.

[0009] According to another aspect of the present invention, there is provided a use of a drug combination of forsythiaside A in the preparation of a drug for treating or preventing hyperlipidemia or atherosclerosis.

[0010] The pharmaceutical composition is prepared by using forsythiaside A as an active ingredient and a pharmaceutical carrier.

[0011] The carrier can be any inert material, organic or inorganic, suitable for enteral, percutaneous or parenteral administration, for example: water, gelatin, gum arabic, lactose, microcrystalline cellulose starch, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talc, colloidal silicon dioxide, etc. The composition may also contain other pharmaceutically active agents, and conventional additives such as stabilizers, wetting agents, emulsifiers, flavoring agents, buffers, etc.

[0012] The pharmaceutical composition is in the form of tablets, capsules, granules, suspensions, dripping pills, injections or aerosols.

[0013] The present invention discovers a new medical use for the known compound Forsythiaside A and opens up a new application field. Forsythiaside A has a strong pharmacological effect and can be used to prepare drugs for preventing and treating hyperlipidemia or atherosclerosis.

[0014] Beneficial effects of the present invention

[0015] The present invention discloses a use of forsythiaside A in preparing drugs for ACLY-related diseases. The compound has significant effects of reducing body weight, blood sugar, triglycerides, cholesterol, etc., and has a clear and highly active ACLY inhibitory effect. The compound has good development prospects in the treatment of ACLY-related diseases.

[0016] In the enzyme activity test, forsythiaside A had a very significant inhibitory effect on ACLY, with a half inhibitory concentration (IC 50) is 0.64±0.09μM; in cell models, Forsythiaside A can significantly reduce triglyceride levels; animal experiments show that Forsythiaside A can reduce the body weight, blood sugar, triglyceride, cholesterol levels, etc. of mice fed a high-fat, high-cholesterol, and high-fructose diet. Therefore, Forsythiaside A has potential therapeutic value for ACLY-related diseases such as hyperlipidemia and atherosclerosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 :Inhibitory activity of forsythiaside A on ACLY

[0018] Figure 2 :Evaluation of the efficacy of forsythiaside A in HepG2 cell model

[0019] Figure 3 :Effects of forsythiaside A on body weight and blood sugar

[0020] Figure 4 :Effects of forsythiaside A on liver and adipose tissue

[0021] Figure 5 :Effects of forsythiaside A on triglycerides and cholesterol DETAILED DESCRIPTION

[0022] The present invention is further described with reference to examples, which are intended to illustrate the present invention but not to limit the present invention.

[0023] The instruments and reagents used in the experiment mainly include: PE Ensight microplate reader (PerkinElmer), ADP-Glo TMKinase Assay kit (Promega), CulturPlate 384-well plate (Perkinelmer), dimethyl sulfoxide (Shanghai Yuanye Biotechnology Co., Ltd.), forsythiaside A (Chengdu Efa Biotechnology Co., Ltd.), oleic acid (Shanghai Macklin Biochemical Technology Co., Ltd.), palmitic acid (Chengdu Pusi Biotechnology Co., Ltd.), tissue cell triglyceride (TG) content enzymatic assay kit (Beijing Pulilai Gene Technology Co., Ltd.), HepG2 cells (Shanghai Cell Bank, Chinese Academy of Sciences), CO2 incubator (Thermo Fisher Scientific, Forma Steri-Cycle), triglyceride (TG) assay kit (Nanjing Jiancheng Bioengineering Institute), total cholesterol (TC) assay kit (Nanjing Jiancheng Bioengineering Institute), blood glucose test strips (Sino), electronic scale (Mettlertoledo), C57BL / 6 mice (Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.), normal feed (Synergy Bio, SWS9102), GAN feed (Research Diets, D09100310), castor oil polyoxyethylene ether (MACKLIN) and normal saline (Shandong Qidu Pharmaceutical Co., Ltd.).

[0024] Example 1: Determination of ACLY inhibitory activity of forsythiaside A

[0025] The stock solution concentration of the forsythiaside A compound is 50mM, and the solvent is dimethyl sulfoxide. Take 1μL of the stock solution and add it to 61.5μL of aqueous buffer to obtain a 0.8mM solution of the compound forsythiaside A; the composition of the aqueous buffer is: in water, a final concentration of 40mM tris (tris), a final concentration of 4mM dithiothreitol, a final mass concentration of 0.01% lauryl alcohol polyoxyethylene ether, 10mM MgCl2, a final volume fraction of 1% dimethyl sulfoxide, pH = 8.0.

[0026] A total of 14 concentration gradients of forsythiaside A working solutions were prepared by gradient dilution of 0.8 mM solution of compound forsythiaside A with aqueous buffer, with concentrations of 0.8 mM, 0.4 mM, 0.2 mM, 0.1 mM, 0.05 mM, 0.025 mM, 0.0125 mM, 0.00625 mM, 0.003125 mM, 0.0015625 mM, 0.00078125 mM, 0.000390625 mM, 0.0001 953125mM and 0.00009765625mM; dilute the ACLY stock solution to 30nM with aqueous buffer to obtain diluted ACLY solution, take 2.5μL of the diluted ACLY solution and place it in a 384-well plate, then take 2.5μL of the above-mentioned forsythiaside A working solution of different concentrations and place it in the above-mentioned 384-well plate containing the diluted ACLY solution; the aqueous stock solution of ATP citrate lyase (ACLY) is composed of: in water, a final concentration of 50mM tris, a final concentration of 400mM NaCl, and a final volume fraction of 10% glycerol.

[0027] The well plate was flicked to mix the liquid in the 384-well plate system evenly, and incubated at room temperature for 15 minutes. Then 5 μL of substrate mixture solution was added to the wells; the substrate mixture solution (final concentration) was: 600 μM citric acid, 150 μM adenosine triphosphate (Promega), 150 μM coenzyme A, and the solvent was water; low-speed centrifugation (1200 rpm, 1 min, 20°C) was performed to mix evenly.

[0028] Then, the 384-well plate was placed in a 37°C incubator for 55 minutes, taken out, and allowed to stand at room temperature for 5 minutes. After returning to room temperature, ADP-Glo ​​was added to each well. TM 10 μL of ADP-Glo ​​reagent in the Kinase Assay kit was reacted at room temperature for 40 min. Then, ADP-Glo ​​was added to each well. TM 20 μL of the kinase detection reagent in the Kinase Assay Kit was incubated at room temperature for 40 min, and then the fluorescence intensity was detected on a PE Ensight microplate reader. GraphPad Prism 6.0 was used to fit the relationship between the concentration and fluorescence intensity of forsythiaside A to obtain the dose-effect curve of compound forsythiaside A ( Figure 1 ), the horizontal axis is the logarithmic value of the molar concentration of the compound forsythiaside A, and the vertical axis is the fluorescence intensity value measured by the instrument. The inhibitory activity of the compound forsythiaside A targeting ACLY is IC 50 =0.64±0.09 μM, indicating that compound forsythiaside A is a highly active inhibitor of ACLY.

[0029] Example 2: Determination of triglyceride levels of forsythiaside A in HepG2 cell models stimulated by oleic acid and palmitic acid

[0030] The stock solution concentration of forsythiaside A is 100 mM, the stock solution concentration of oleic acid is 1000 mM, and the stock solution concentration of palmitic acid is 100 mM, and their solvents are all dimethyl sulfoxide.

[0031] The seeding density in a 6-well plate was 4 × 10 5 HepG2 cells per well were cultured in a CO2 incubator in an atmosphere of 5% CO2 by volume and at 37°C for 18-24 h (here 24 h), and then divided into three groups, namely the control group (no oleic acid, palmitic acid and drugs were added, and the volume of dimethyl sulfoxide added was the same as the volume of the stock solution of forsythiaside A added to the drug group), the model group (the stock solution of oleic acid and the stock solution of palmitic acid were added to make the final molar concentrations of oleic acid and palmitic acid 0.67 mM and 0.33 mM, respectively, and the volume of dimethyl sulfoxide added was the same as the volume of the stock solution of forsythiaside A added to the drug group), and the drug group (the stock solution of oleic acid and the stock solution of palmitic acid were added to make the final molar concentrations of oleic acid and palmitic acid 0.67 mM and 0.33 mM, respectively, and the stock solution of forsythiaside A was added to make the molar concentration of forsythiaside A 50 μM). After 48 h of drug treatment, the triglyceride content was determined according to the instructions of the kit for enzymatic determination of triglyceride content in tissue cells. Figure 2 Compared with the control group, the triglyceride level in the model group was significantly increased, indicating that the high-fat model of HepG2 cells induced by oleic acid and palmitic acid was successful; compared with the model group, the triglyceride level in the group treated with Forsythiaside A was significantly decreased, indicating that Forsythiaside A can reduce the triglyceride level in HepG2 cells induced by oleic acid and palmitic acid.

[0032] Example 3: Forsythiaside A reduces body weight and blood glucose in mice induced by GAN diet

[0033] The dosage of forsythiaside A for mice is 20 mg (mass of forsythiaside A) / kg (mouse body weight), and the volume ratio of the solvent is dimethyl sulfoxide: anhydrous ethanol: a mixture of castor oil polyoxyethylene ether and normal saline = 1:2:97, wherein the volume ratio of castor oil polyoxyethylene ether and normal saline in the mixture is 1:9. The concentration of forsythiaside A in the solvent is 2 mg / mL.

[0034] In this experiment, 8-week-old healthy male C57BL / 6 mice were selected and purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. The experiment was divided into 3 groups, namely the control group (given normal feed), the model group (GAN feed), and the drug-treated group (GAN feed + Forsythiaside A group). During the experiment, the mice were induced by 14 weeks of GAN feed feeding (free feeding) + 8 weeks of Forsythiaside A (20 mg / kg). The drug-treated group was given Forsythiaside A for 8 weeks, and the control group and the model group (free feeding) were given 8 weeks of solvent induction (intraperitoneal injection) with the same volume ratio, once a day. During the modeling process, the mice were weighed and their blood sugar was tested every week. Figure 3 At the 22nd week, the body weight of mice in the model group was significantly increased compared with that in the control group, indicating that the high-fat model induced by GAN feed was successful; the body weight and blood sugar of the drug-treated group were significantly decreased compared with those in the model group, indicating that Forsythiaside A can reduce the body weight and blood sugar of mice after GAN feed induction.

[0035] Example 4: Forsythiaside A reduces the weight of liver, mesenteric fat, gonadal fat, and perirenal fat in mice induced by GAN diet.

[0036] At the end of 22 weeks, the experimental mice of Example 3 were killed, and the liver, mesenteric fat, gonadal fat, and perirenal fat were weighed. Figure 4 Compared with the control group mice, the weights of the liver, mesenteric fat, gonadal fat, and perirenal fat of the model group mice were significantly increased, indicating that the high-fat model induced by GAN feed was successful and caused liver hypertrophy in mice; compared with the model group mice, the weights of the liver, mesenteric fat, gonadal fat, and perirenal fat of the Forsythiaside A-treated group were significantly decreased, indicating that Forsythiaside A can reduce lipid accumulation and liver hypertrophy induced by GAN feed.

[0037] Example 5: Forsythiaside A reduces triglyceride and cholesterol levels in mice induced by GAN diet

[0038] Accurately weigh the experimental mouse liver tissue of Example 3, add 9 times the volume of homogenization medium (absolute ethanol) at a weight (g): volume (ml) ratio of 1:9, mechanically homogenize under ice water bath conditions, centrifuge at 2500 rpm for 10 minutes, and take the supernatant to measure triglyceride and cholesterol according to the kit instructions. Figure 5 Compared with the control group, the triglyceride and cholesterol levels in the model group were significantly increased, indicating that the blood lipid level in mice was significantly increased and metabolic disorders occurred after GAN feed feeding; compared with the model group, the triglyceride and cholesterol levels in the Forsythiaside A group were significantly decreased, indicating that Forsythiaside A has a potential therapeutic effect on hyperlipidemia and atherosclerosis.

Claims

1. Use of forsythiaside A in the preparation of drugs for ACLY-related diseases or drugs for inhibiting ACLY activity.

2. The use according to claim 1, characterized in that The structure of the forsythiaside A is as follows: It has significant inhibitory activity on ATP citrate lyase, 3. The use according to claim 1, characterized in that The ATP citrate lyase-related disease is one or more of hyperlipidemia or atherosclerosis.

4. The use according to claim 3, characterized in that The drug for inhibiting the activity of ATP citrate lyase can reduce the synthesis of cholesterol and / or triglyceride by inhibiting the activity of ATP citrate lyase.

5. A pharmaceutical composition, characterized in that The invention is a pharmaceutical composition prepared by using forsythiaside A as an active ingredient and a pharmaceutical carrier or a pharmaceutically acceptable carrier or auxiliary material.

6. The pharmaceutical composition according to claim 5, characterized in that: The pharmaceutical composition is in the form of tablets, capsules, granules, suspensions, dropping pills, injections or aerosols.

Citation Information

Cited By

  • Application of forsythiaside A in preparation of medicine for preventing and / or treating porcine contagious pleuropneumonia

    CN120549946A

  • Application of forsythoside A in the preparation of drugs for the prevention and / or treatment of porcine contagious pleuropneumonia

    CN120549946B